SCHEMBL833766

SCHEMBL833766

COc1c(Cc2ccc(C)cc2)cc(C=O)c2c1CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CNR2 P34972 3/20 0.36
MCL1 Q07820 1/20 0.34
GPR55 Q9Y2T6 2/20 0.34
CNR1 P21554 1/20 0.34
SLC5A2 P31639 5/20 0.34
SLC5A1 P13866 4/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TUBB1 Q9H4B7 1/20 0.33
THRA P10827 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL834457 0.77 MEN1 (0.50) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL836196 0.75 MAOA (0.36) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL23713494 0.75 MEN1 (0.43) MEN1KMT2AALDH1A1L3MBTL1CNR2
SCHEMBL11624509 0.72 MEN1 (0.49) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL836902 0.71 MEN1 (0.48) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL835754 0.71 MEN1 (0.48) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL11629474 0.70 LMNA (0.46) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL23713275 0.69 RXRA (0.41) MEN1KMT2ALMNACNR2CNR1
SCHEMBL5665974 0.69 MEN1 (0.43) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL836048 0.68 MEN1 (0.42) MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378118-B2 Pyrazole-based thyroid receptor compounds TORRENT PHARMACEUTICALS LTD. (IN) 2013-02-19 US disclosed
US-20120202816-A1 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS, LTD. (IN) 2012-08-09 US disclosed
US-8143424-B2 Thyroid like compounds TORRENT PHARMACEUTICALS LTD. (IN) 2012-03-27 US disclosed
EP-2061766-B1 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS LTD (IN) 2010-08-18 EP disclosed
US-20100168110-A1 Novel Compounds TORRENT PHARMACEUTICALS LTD. (IN) 2010-07-01 US disclosed
EP-2061766-A2 NOVEL COMPOUNDS Torrent Pharmaceuticals Ltd (IN) 2009-05-27 EP disclosed
WO-2008149379-A2 NOVEL COMPOUNDS TORRENT PHARMACEUTICALS LTD. (IN) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202816-A1 NOVEL COMPOUNDS TSHR, THRB, GPR119 MEN1 541/4885KMT2A 3000/4885ALDH1A1 1664/4885
US-20100168110-A1 Novel Compounds TSHR, THRB, GPR119 MEN1 541/4885KMT2A 3000/4885ALDH1A1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.